|
24 Companies |
|
9 Products |
|
9 Products |
|
6 Mechanisms of Action |
|
50 Trials |
|
3648 News |
|
| «12...48495051525354555657585960» |
- | octreotide acetate solution for injection / Generic mfg.
Trial completion: Octreotide Efficacy and Safety in First-line Acromegalic Patients (clinicaltrials.gov) - Feb 24, 2017
P4, N=20, Completed, Sponsor: Novartis Pharmaceuticals
Suspended --> Completed
- | Trial primary completion date: Pituitary Histopathology and Hyperprolactinaemia and Risk of Glucose Metabolic Disturbances in Acromegaly. (clinicaltrials.gov) - Feb 23, 2017
P=N/A, N=79, Active, not recruiting, Sponsor: Rigshospitalet, Denmark
Suspended --> Completed Trial primary completion date: Dec 2016 --> Apr 2017
- | TBR-065 / Tiburio
New P2a trial: DOPAACRO 002: Assessment of BIM23B065, Given as Repeated Subcutaneous Injection in Subjects With Acromegaly (clinicaltrials.gov) - Feb 7, 2017
P2a, N=24, Recruiting, Sponsor: Ipsen
- ||| New trial: Treatment Patterns and Treatment Outcomes for Acromegaly (clinicaltrials.gov) - Feb 6, 2017
P=N/A, N=520, Recruiting, Sponsor: Columbia University
- New trial: Developing a Simple Recognition System of Acromegaly (clinicaltrials.gov) - Feb 2, 2017
P=N/A, N=80, Recruiting, Sponsor: National Taiwan University Hospital
- Somavert (pegvisomant) / Pfizer
Trial primary completion date: Acromegaly Combination Treatment Study (clinicaltrials.gov) - Feb 1, 2017
P=N/A, N=51, Recruiting, Sponsor: Cedars-Sinai Medical Center
Trial primary completion date: Dec 2016 --> Apr 2017 Trial primary completion date: Dec 2017 --> Dec 2018
- || Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Biomarker, Trial primary completion date: SOPRANo: Somatuline Predictive Factors in Acromegaly and NET (clinicaltrials.gov) - Jan 31, 2017
P=N/A, N=156, Active, not recruiting, Sponsor: Ipsen
Trial primary completion date: Dec 2017 --> Dec 2018 Trial primary completion date: Dec 2016 --> Jul 2016
- octreotide acetate / Generic mfg.
Trial completion, Trial primary completion date: Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target (clinicaltrials.gov) - Jan 26, 2017
P4, N=84, Completed, Sponsor: University of Aarhus
Trial primary completion date: Dec 2016 --> Jul 2016 Active, not recruiting --> Completed | Trial primary completion date: Jun 2015 --> Jan 2017
- |||| Signifor LAR (pasireotide long acting release) / Recordati
Trial primary completion date: Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues (clinicaltrials.gov) - Jan 18, 2017
P3, N=112, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed | Trial primary completion date: Jun 2015 --> Jan 2017 Trial primary completion date: Aug 2018 --> Jan 2018
- ||| Signifor LAR (pasireotide long acting release) / Recordati
Trial initiation date: Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies (clinicaltrials.gov) - Jan 4, 2017
P4, N=400, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Aug 2018 --> Jan 2018 Initiation date: Jun 2013 --> Dec 2012
- Enrollment status, Trial primary completion date: Growth Hormone, IGF-1 and Medical Treatment in Acromegaly: Are There Effects on Gut Hormone Physiology and Postprandial Substrate Metabolism? (clinicaltrials.gov) - Dec 8, 2016
P=N/A, N=50, Enrolling by invitation, Sponsor: University Hospital, Ghent
Initiation date: Jun 2013 --> Dec 2012 Recruiting --> Enrolling by invitation | Trial primary completion date: Jul 2015 --> May 2017
- |||| Signifor (pasireotide) / Recordati
Trial completion: Study Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in Acromegalic Patients (clinicaltrials.gov) - Nov 6, 2016
P2, N=62, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Enrolling by invitation | Trial primary completion date: Jul 2015 --> May 2017 Active, not recruiting --> Completed
- Somavert (pegvisomant) / Pfizer
New P3 trial: I-Con Study: Strict IGF-1 Control in Acromegaly (clinicaltrials.gov) - Nov 2, 2016
P3, N=35, Not yet recruiting, Sponsor: St. Michael's Hospital, Toronto
- || Enrollment closed: Validation Study of the SAGIT (clinicaltrials.gov) - Oct 25, 2016
P=N/A, N=200, Active, not recruiting, Sponsor: Ipsen
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || lignocaine / Generic mfg.
New P2/3 trial: ultradian: Dynamic Hormone Diagnostics in Endocrine Disease (clinicaltrials.gov) - Oct 17, 2016
P2/3, N=350, Not yet recruiting, Sponsor: Haukeland University Hospital
- Trial primary completion date, Surgery: Rhinological Outcomes in Endonasal Pituitary Surgery (clinicaltrials.gov) - Oct 12, 2016
P=N/A, N=200, Active, not recruiting, Sponsor: St. Joseph's Hospital and Medical Center, Phoenix
Recruiting --> Active, not recruiting Trial primary completion date: Sep 2016 --> Sep 2017
- ||| Signifor LAR (pasireotide long acting release) / Recordati
Enrollment change, Trial primary completion date: Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly (clinicaltrials.gov) - Oct 11, 2016
P4, N=246, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Sep 2016 --> Sep 2017 N=176 --> 246 | Trial primary completion date: Sep 2017 --> May 2018
- | Oclaiz (octreotide subcutaneous depot) / Camurus
Trial completion, Enrollment change: Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) (clinicaltrials.gov) - Oct 11, 2016
P2, N=12, Completed, Sponsor: Camurus AB
N=176 --> 246 | Trial primary completion date: Sep 2017 --> May 2018 Active, not recruiting --> Completed | N=24 --> 12
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Enrollment change, Trial termination, Trial primary completion date: ACRO-OPTIM: Therapeutic Strategies in Acromegalic Subjects Treated With Lanreotide 120mg (clinicaltrials.gov) - Oct 3, 2016
P=N/A, N=4, Terminated, Sponsor: Ipsen
Active, not recruiting --> Completed | N=24 --> 12 N=183 --> 4 | Recruiting --> Terminated | Trial primary completion date: Oct 2019 --> Jan 2016; The study was terminated early due to insufficient potential for recruitment.
- Trial primary completion date: Assessment of Changes in Metabolic Activity in Liver & Skeletal Muscle in Patients Suffering From Acromegaly (clinicaltrials.gov) - Sep 27, 2016
P4, N=24, Recruiting, Sponsor: Medical University of Vienna
N=183 --> 4 | Recruiting --> Terminated | Trial primary completion date: Oct 2019 --> Jan 2016; The study was terminated early due to insufficient potential for recruitment. Trial primary completion date: May 2016 --> May 2017
- Trial primary completion date: Brain-gut Interaction in Irradiated Patients With Acromegaly (clinicaltrials.gov) - Sep 20, 2016
P=N/A, N=36, Active, not recruiting, Sponsor: Rigshospitalet, Denmark
Trial primary completion date: May 2016 --> May 2017 Trial primary completion date: Jul 2016 --> Jul 2017
- Trial primary completion date: Ectopic Lipid Deposition and Insulin Resistance in After Treatment of Acromegaly (clinicaltrials.gov) - Sep 15, 2016
P=N/A, N=46, Active, not recruiting, Sponsor: Massachusetts General Hospital
Trial primary completion date: Jul 2016 --> Jul 2017 Trial primary completion date: Jul 2016 --> Jan 2017
- || Trial primary completion date, HEOR: Acromegaly Treatment Quality of Life Study (clinicaltrials.gov) - Sep 15, 2016
P=N/A, N=120, Recruiting, Sponsor: Massachusetts General Hospital
Trial primary completion date: Jul 2016 --> Jan 2017 Trial primary completion date: Jul 2016 --> Feb 2017
- Trial primary completion date: Substrate Metabolism and Insulin Sensitivity in Acromegalic Patients Before and After Treatment (clinicaltrials.gov) - Aug 12, 2016
P=N/A, N=20, Recruiting, Sponsor: University of Aarhus
Trial primary completion date: Jul 2016 --> Feb 2017 Trial primary completion date: Aug 2015 --> Jan 2017
- Trial primary completion date: IGF-I and Free Fatty Acids Isn Glucose Metabolism in Acromegaly (clinicaltrials.gov) - Aug 8, 2016
P=N/A, N=20, Recruiting, Sponsor: Carol Davila University of Medicine and Pharmacy
Trial primary completion date: Aug 2015 --> Jan 2017 Trial primary completion date: Dec 2015 --> Dec 2016
- Trial primary completion date: A Prospective Study of Outcome After Therapy for Acromegaly (clinicaltrials.gov) - Aug 8, 2016
P=N/A, N=250, Recruiting, Sponsor: Columbia University
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Jun 2016 --> Jun 2020
- ||| Signifor LAR (pasireotide long acting release) / Recordati
Enrollment change: Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly (clinicaltrials.gov) - Aug 8, 2016
P4, N=176, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jun 2016 --> Jun 2020 N=133 --> 176
- ||| Signifor LAR (pasireotide long acting release) / Recordati
Enrollment change: Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies (clinicaltrials.gov) - Aug 8, 2016
P4, N=400, Recruiting, Sponsor: Novartis Pharmaceuticals
N=133 --> 176 N=220 --> 400
- ||| Somavert (pegvisomant) / Pfizer, Signifor LAR (pasireotide long acting release) / Recordati
Enrollment closed, Combination therapy: PAPE: Pasireotide LAR and Pegvisomant Study in Acromegaly (clinicaltrials.gov) - Aug 3, 2016
P4, N=60, Active, not recruiting, Sponsor: Erasmus Medical Center
N=220 --> 400 Recruiting --> Active, not recruiting
- || Trial primary completion date: Validation Study of the SAGIT (clinicaltrials.gov) - Jul 29, 2016
P=N/A, N=200, Recruiting, Sponsor: Ipsen
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2018 --> Sep 2018
- ||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Enrollment open: SOMACROL: Lanreotide Autogel 120 mg at Extended Dosing Intervals (>4 Weeks) in Acromegalic Subjects (clinicaltrials.gov) - Jul 29, 2016
P=N/A, N=150, Recruiting, Sponsor: Ipsen
Trial primary completion date: Jun 2018 --> Sep 2018 Not yet recruiting --> Recruiting
- ||||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Enrollment closed, Trial primary completion date: LANTERN: Efficacy and Safety of Lanreotide Autogel (clinicaltrials.gov) - Jul 1, 2016
P3, N=128, Active, not recruiting, Sponsor: Ipsen
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2017 --> Nov 2016
- Trial primary completion date, Surgery: Rhinological Outcomes in Endonasal Pituitary Surgery (clinicaltrials.gov) - Jun 23, 2016
P=N/A, N=200, Active, not recruiting, Sponsor: St. Joseph's Hospital and Medical Center, Phoenix
Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2017 --> Nov 2016 Trial primary completion date: May 2016 --> Sep 2016
- ||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
New trial: SOMACROL: Lanreotide Autogel 120 mg at Extended Dosing Intervals (>4 Weeks) in Acromegalic Subjects (clinicaltrials.gov) - Jun 21, 2016
P=N/A, N=150, Not yet recruiting, Sponsor: Ipsen
- | Trial completion: Phase II Study With ITF2984 in Acromegalic Patients (clinicaltrials.gov) - Jun 16, 2016
P2, N=48, Completed, Sponsor: Italfarmaco
Trial primary completion date: May 2016 --> Sep 2016 Active, not recruiting --> Completed
- Signifor LAR (pasireotide long acting release) / Recordati
Trial primary completion date: Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism (clinicaltrials.gov) - Jun 15, 2016
P2, N=33, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Trial primary completion date: May 2016 --> Feb 2017
- ||| New trial: ACROSAS: Prevalence of Acromegaly in a Diagnostic Consultation for Sleep Apnea Syndrome (clinicaltrials.gov) - Jun 4, 2016
P=N/A, N=880, Completed, Sponsor: University Hospital, Grenoble
- ||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial completion: SODA: Somatuline (clinicaltrials.gov) - May 31, 2016
P=N/A, N=260, Completed, Sponsor: Ipsen
Trial primary completion date: May 2016 --> Feb 2017 Active, not recruiting --> Completed
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial primary completion date: Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly (clinicaltrials.gov) - May 31, 2016
P2a, N=27, Recruiting, Sponsor: Ipsen
Active, not recruiting --> Completed Trial primary completion date: Feb 2017 --> Jun 2018
- || Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Enrollment closed, HEOR: ACRO QLQ: Quality of Life (QoL) in Subjects With Acromegaly Under Lanreotide Autogel (clinicaltrials.gov) - May 31, 2016
P=N/A, N=150, Active, not recruiting, Sponsor: Ipsen
Trial primary completion date: Feb 2017 --> Jun 2018 Recruiting --> Active, not recruiting
- Enrollment closed, Trial primary completion date: Ectopic Lipid Deposition and Insulin Resistance in After Treatment of Acromegaly (clinicaltrials.gov) - May 4, 2016
P=N/A, N=46, Active, not recruiting, Sponsor: Massachusetts General Hospital
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2016 --> Jul 2016
- Trial primary completion date: Pituitary Histopathology and Hyperprolactinaemia and Risk of Glucose Metabolic Disturbances in Acromegaly. (clinicaltrials.gov) - Apr 7, 2016
P=N/A, N=79, Active, not recruiting, Sponsor: Rigshospitalet, Denmark
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2016 --> Jul 2016 Trial primary completion date: Dec 2014 --> Dec 2016
- Trial primary completion date: Brain-gut Interaction in Irradiated Patients With Acromegaly (clinicaltrials.gov) - Apr 7, 2016
P=N/A, N=36, Active, not recruiting, Sponsor: Rigshospitalet, Denmark
Trial primary completion date: Dec 2014 --> Dec 2016 Trial primary completion date: Feb 2015 --> Jul 2016
- Trial completion: Somatostatin Analogue Treatment of Acromegaly: Molecular Aspects (clinicaltrials.gov) - Apr 7, 2016
P=N/A, N=18, Completed, Sponsor: University of Aarhus
Trial primary completion date: Feb 2015 --> Jul 2016 Active, not recruiting --> Completed
- |||||| Enrollment open, Patient reported outcomes: MPOWERED: Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly (clinicaltrials.gov) - Mar 19, 2016
P3, N=150, Recruiting, Sponsor: Chiasma, Inc.
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial completion, Enrollment change, Trial primary completion date, Surgery: A Pilot Study of Pre- and Post-operative Use of Somatuline Depot. (clinicaltrials.gov) - Mar 16, 2016
P4, N=4, Completed, Sponsor: John Wayne Cancer Institute
Not yet recruiting --> Recruiting Recruiting --> Completed | N=24 --> 4 | Trial primary completion date: Sep 2016 --> Jan 2016
- Oclaiz (octreotide subcutaneous depot) / Camurus
Trial primary completion date: Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) (clinicaltrials.gov) - Mar 15, 2016
P2, N=24, Active, not recruiting, Sponsor: Camurus AB
Recruiting --> Completed | N=24 --> 4 | Trial primary completion date: Sep 2016 --> Jan 2016 Trial primary completion date: Feb 2016 --> May 2016
- || Trial primary completion date: Ectopic Lipid Deposition and Insulin Resistance in After Treatment of Acromegaly (clinicaltrials.gov) - Mar 10, 2016
P=N/A, N=52, Recruiting, Sponsor: Massachusetts General Hospital
Trial primary completion date: Feb 2016 --> May 2016 Trial primary completion date: Nov 2015 --> Apr 2016
- || Trial primary completion date, HEOR: Acromegaly Treatment Quality of Life Study (clinicaltrials.gov) - Mar 10, 2016
P=N/A, N=120, Recruiting, Sponsor: Massachusetts General Hospital
Trial primary completion date: Nov 2015 --> Apr 2016 Trial primary completion date: Nov 2015 --> Jul 2016
- ||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
New trial: ACRO-OPTIM: Therapeutic Strategies in Acromegalic Subjects Treated With Lanreotide 120mg (clinicaltrials.gov) - Mar 4, 2016
P=N/A, N=183, Recruiting, Sponsor: Ipsen